Introduction ·004
Glossary of Terms ·010

Part 1: GLP-1, Who Are You?

01 Getting Familiar with GLP-1 ·022
02 The War on Life, the Evolution of Medicine ·032
03 GLP-1 Commercialization Process ·040
04 Disease-Specific Effects of GLP-1 Drugs ·049
05 Obesity and GLP-1 ·059
06. Why Won't My Body Listen to Me? ·074

Part 2: Practical Use of GLP-1

07 GLP-1 Injections: Let's Inject Them into Your Belly! ·086
08 Side Effects of GLP-1 Drugs ·098
09 Side Effects That Aren't Side Effects ·108
10 The Yo-Yo War Begins as Soon as You Stop Medication ·117
11 The Need for Lifestyle Correction and Exercise ·121
12 What and how much to eat? ·131
13 Practical Exercise Methods When Using GLP-1 Drugs ·144

Part 3: The Future of GLP-1 Drugs

14 Endless Evolution, Next-Generation GLP-1 ·154
Beyond Ambassador 15, GLP-1 Multi-Effect ·158

GLP-1 Hotline: Key Q&A ·164
#01 Are GLP-1 drugs really popular these days?
#02 What medication should I start taking to control my weight?
#03 Can I use Wegobi even if I am not severely obese?
#04 I heard that I can get the Wegobi at half price. How do I do that?
#05 If I take the medicine, will I lose weight right away?
#06 How long should I take the medication once I start?
#07 What percentage actually stop taking their medication?
#08 Are the side effects really that serious?
#09 Is there any way to reduce nausea?
#10 Are there people who should avoid Vigovi or Saxenda?
#11 Are there any medications that should not be taken together?
#12 Can I use it while pregnant or breastfeeding?
#13 I forgot to take my shot. Is it okay to get it a day or two late?
#14 I have polycystic ovary syndrome. Can I take GLP-1 drugs?
#15 I have frequent bruises after getting a haircut. Is there a solution?
#16 I'm very tired. What should I do?
#17 I got constipated after taking the pill.
How do I solve this?
#18 How can I prevent Ozempic Face?
#19 Will it be easier to lose weight if I record it?

Outgoing Post ·186
References ·190
Acknowledgments ·194

“Should I write this or not? Can I use the Wegobi?”
If you have to use it, use it knowingly!
A Guide to Wegobi from a Practical Doctor

“One of the things I realized when I first started taking GLP-1 was that I had always thought that skinny people just had more willpower.
I thought they were eating healthier, sticking to it for longer, and never eating things like potato chips. When I first tried GLP-1, I realized, "Oh! They weren't even thinking about that."
“Eat only when you’re hungry, and stop when you’re full.”

This is what Oprah Winfrey said about Wegobi on her talk show.
He confessed that he thought everyone else suffered from 'food noise', where thoughts of food would always be in his head, like he did, but after using the GLP-1 drug (Wigobi), he realized that the noise had disappeared.
As celebrities, including Oprah, have confessed, stomach-busting drugs work by inducing feelings of fullness and slowing stomach emptying, thereby drowning out the "food noise" in your head.
As your appetite disappears, you eat less food and lose weight naturally, just like on a low-calorie diet.
While previous obesity treatments used methods such as inhibiting fat absorption, increasing metabolic rate, or suppressing appetite in the brain, Wegobi is a drug that adheres to the principle that 'if you burn more calories than you take in, you lose weight.'

But as is often the case with new drugs, there is hesitation about their use until a large body of evidence is gathered from long-term, widespread use.
The media sensationalizes reports of side effects such as pancreatitis, hair loss, and blindness after using Wegobi.
People around me who have used Wegobi also exaggerate the gastrointestinal symptoms they experienced, such as nausea and indigestion.
However, it is difficult to determine how much of this information is true.
Whether you're a healthcare provider or a dieter, you'll ultimately have to decide whether to take the popular new drug called Wegobi.
What is needed for this decision is sound information that weighs the complications that overweight or obesity itself causes against the beneficial effects of medications, and the potential side effects of medications like Wegobi.
Written by a practicing physician, "Wigobi (GLP-1) User Manual for Successful Dieting" details the drug development process, objective medical knowledge, drug functions, and types of possible side effects, providing readers with a basis for making their own judgments.

How has obesity been treated so far?
What exactly is this new GLP-1 drug?
Finding the medical roots of the medicine I use on my precious body

In 1932, Belgian physiologist Jean La Barre proposed the scientific idea that our bodies secrete gut hormones called incretins that stimulate insulin secretion, and that these hormones could improve diabetes.
Although the existence of incretins was predicted, it was not until 1983 that humans were able to discover one of them, GLP-1.
However, discovery alone cannot perfect a drug.

It was only after scientists discovered exendin-4, a hormone structurally similar to GLP-1, in the saliva of the North American desert dragon that they were able to synthesize it and develop it into a drug.
Since then, researchers have developed drugs that reduce antibody production and extend half-life, and eventually, diabetes drugs such as Ozempic and obesity drugs such as Saxenda, Wigovi, and Zebbound have been released on the market.
In this way, the book provides fascinating information not only on the use of GLP-1 drugs, but also on the history of their discovery and development.

GLP-1 drugs were initially noted as diabetes medications because of their blood sugar-lowering effects, but soon became more famous as obesity treatments when their excellent weight-loss effects were discovered.
Saxenda, which is injected once a day, Wigobi, which is injected once a week and reduces body weight by about 15%, and Zebbound, which reduces body weight by up to 22.5%, are the most commonly heard names.
Since it is also effective as a diabetes medication, the 『Wigobi (GLP-1) User Manual for Successful Dieting』 provides specific information on the relationship between diabetes and obesity, the mechanism of its effectiveness as a diabetes medication, and its effect on cardiovascular disease, which is a comorbidity of diabetes.
A chapter is devoted to the most important weight loss mechanism, detailing why appetite suppression occurs and the effects of delayed gastric emptying.
As we live in an era where obesity must be managed as a chronic disease, understanding accurate information about GLP-1 drugs will be useful for ongoing health management.

What if I don't lose weight even after using Wegobi?
How severe are the side effects of Wegobi?
Treatment of Wegobi through Scientific Data

Studies have shown that the average weight loss when using Wegobi is 14.9%, but the response range is very wide.
It is normally distributed from non-responders (less than 5% body weight loss) to average responders and over-responders (maximum body weight loss).
What factors contribute to these individual differences in response? This question is crucial, as accurately analyzing these factors is crucial for determining medication dosage and responding appropriately.
The "GLP-1 User Manual for Successful Dieting" divides these factors into two major categories.
There are four things I can change and four things I cannot change.
Factors that can be changed include living environment, eating habits, gut microbiota, presence or absence of type 2 diabetes, and concomitant medications, while factors that cannot be changed include genetic factors, beta cell function, age, gender, and presence or absence of concomitant diseases.

By analyzing these factors, readers can identify 'changeable factors' in advance and apply them to effective weight loss.
In addition, side effects were covered in detail so that possible side effects could be identified and prepared for in advance.
When we looked at the statistics on why people who want to lose weight hesitate to use Wegobi, 42% said it was because of concerns about side effects, and 29% said it was because of aversion to the injections that have to be administered every week.
Considering the side effects of obesity itself, such as metabolic disorders, kidney disease, and fatty liver disease, accurately assessing the severity and frequency of these side effects helps ensure proper drug use. This article covers not only current GLP-1 drugs but also the next-generation drugs expected in the future.
We introduce oral GLP-1 drugs that have already received FDA approval and are being prepared for introduction in Korea, as well as small molecule oral agents and monthly injections that are under development.
It also includes the effectiveness and development efforts of GLP-1 drugs that can be expected to treat kidney disease, fatty liver disease, dementia, and Parkinson's disease in the future.

If you use Wegobi today
How should I exercise and eat?
Questions about Wegobi confirmed through Q&A

Will using Wegobi lead to weight loss on its own? Will fat disappear magically, without any diet or exercise? The bottom line is that GLP-1 drugs reduce weight by suppressing appetite, but adjusting your eating habits is essential to minimize side effects and prepare for the aftermath of the drug's effects.
In addition, exercise is essential to maintain muscle mass, strengthen cardiopulmonary function, and maintain lost weight.
First, to control food intake, you need to calculate your daily protein needs when using GLP-1 drugs.
Multiply your body weight (kg) by 1.3 to calculate how much protein (g) you should consume per day.
In addition, the book presents basic information on the diet to be aware of while using Wegobi, starting with hydration, the types and intake of fiber, vegetables, fats, and carbohydrates, and the order of meals.
Caution is needed as eating can worsen side effects such as nausea, vomiting, diarrhea, and constipation, and can lead to side effects such as a sudden, aged appearance (ozempic face).

Exercise practice must be specific.
The author provides a basic formula for preventing muscle loss when using GLP-1 drugs, and provides a comprehensive guide, including the order and intensity of three types of exercise: aerobic exercise, interval training, and resistance training.
Furthermore, it emphasizes the recognition that overweight and obesity are chronic conditions requiring long-term management and the importance of focusing on habit formation. "Wigobi (GLP-1) User Manual for Successful Dieting," a practical guide to assisting with the immediate use of GLP-1 drugs, also provides detailed instructions on how to use Wigobi injections and a roadmap for increasing and maintaining doses.
User-centered guides, such as the practical redefinition of 'Response and Non-Response', are particularly useful.
Pharmaceutical companies define non-responders based on the rate of weight loss, so if a patient does not lose 5% of their body weight over a certain period of time, they consider them non-responsive. However, in practice, it is reasonable to define non-responders as “no appetite suppression, no increase in satiety, and no decrease in food desire” and adjust the dosage.

In addition, the "GLP-1 Hotline Key Q&A" provides answers to almost all questions that drug users may have, including how to resolve and take precautions for various side effects such as nausea, constipation, and fatigue that may be encountered while using Wegobi, as well as how to prevent Ozempic phase.
In particular, we have provided medication and weight management notes that allow readers to check the weight control process at a glance to help them use medication.
Anyone considering using GLP-1 drugs such as Wegobi will be able to confidently embark on a healthy diet with just this one book.